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Abstract: Thymidylate synthase (TS) is a prominent drug target for different cancer types.
However, the prolonged use of its classical inhibitors, substrate analogs that bind at the active
site, leads to TS overexpression and drug resistance in the clinic. In the effort to identify anti-TS
drugs with new modes of action and able to overcome platinum drug resistance in ovarian cancer,
octapeptides with a new allosteric inhibition mechanism were identified as cancer cell growth
inhibitors that do not cause TS overexpression. To improve the biological properties, 10 cyclic peptides
(cPs) were designed from the lead peptides and synthesized. The cPs were screened for the ability
to inhibit recombinant human thymidylate synthase (hTS), and peptide 7 was found to act as an
allosteric inhibitor more potent than its parent open-chain peptide [Pro3]LR. In cytotoxicity studies
on three human ovarian cancer cell lines, IGROV-1, A2780, and A2780/CP, peptide 5 and two other
cPs, including 7, showed IC50 values comparable with those of the reference drug 5-fluorouracil, of
the open-chain peptide [d-Gln4]LR, and of another seven prolyl derivatives of the lead peptide LR.
These promising results indicate cP 7 as a possible lead compound to be chemically modified with
the aim of improving both allosteric TS inhibitory activity and anticancer effectiveness.
Keywords: cyclic peptides; enzyme inhibition; thymidylate synthase inhibitors; allosteric inhibitors;
anticancer agents; ovarian cancer
1. Introduction
Human thymidylate synthase (hTS) is a homodimeric protein involved in the folate metabolic
pathway. It catalyzes the reductive methylation of 2′-deoxyuridine-5′-monophosphate (dUMP) to
2′-deoxythymidine-5′-monophosphate (dTMP) using the cofactor N5,N10-methylentetrahydrofolate
(mTHF) [1]. It also regulates protein synthesis by interacting with its own mRNA as well as the mRNAs
of other proteins involved in cell cycle and cell death [2–5]. hTS is largely expressed in different cancer
types such as colorectal cancer, pancreatic cancer, and mesothelioma [6–9]. Thus, it is an important
drug target for different cancer types. The clinically approved 5-fluorouracil (5-FU, the prodrug
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of 5-fluoro-2′-deoxyuridine-5′-monophosphate), raltitrexed (RTX) [10], and pemetrexed (PMX) [11]
are TS-directed drugs acting as folate cofactor analogs. However, their prolonged use leads to hTS
overexpression and results in drug resistance [12]. Our studies are focused on ovarian cancer, a severe
pathology that affects 5% of women of all ages. The starting therapy relays on platinum drugs in
combination with paclitaxel or doxorubicin. However, approximately 70% relapse due to insurgence
of platinum drug resistance [13]. The resistant cancer type shows higher than normal levels of proteins
involved in the replication pathways, including hTS, and cross-resistance with anti-hTS drugs [14–16]
The above-mentioned anti-hTS drugs become ineffective. Therefore, we aimed at overcoming such a
resistance mechanism by discovering new anti-TS drugs with modes of action different from those of
the substrate or cofactor analogs.
To this aim, we previously identified some small peptidic inhibitors that mime a portion of the
monomer–monomer interfacial region in the hTS dimer and bind therein [17–21]. More precisely, from a
parent peptide, C20, whose sequence came from the interface region of hTS (Figure 1A), we synthesized
a series of octapeptides. Two of them, LR (Leu1-Ser2-Cys3-Gln4-Leu5-Tyr6-Gln7-Arg8) and its more
rigid diastereomer [d-Gln4]LR, proved to be allosteric inhibitors of the dimeric enzyme by stabilizing
its di-inactive form, thus reducing the protein catalytic activity (Figure 1B) [17,21].
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Figure 1. (A) Monomer of hTS (in red cartoon, PDB: 3N5E) with, highlighted in green, the region
corresponding to the C20 peptide. (B) Crystal structure of the complex of hTS with the LR peptide
(PDB: 3N5E). (C) Close-up on the cone-shaped binding cavity of the LR peptide in the interface between
the two hTS monomers. (D) View from below of the cone-shape binding cavity, highlighting the
helical-type conformations assumed by the LR peptide. The two monomers of hTS are represented in
red and cyan cartoons; the LR peptide is represented in green ribbon.
These peptides induced cancer cell growth inhibition in both platinum-sensitive and -resistant
ovarian cancer cells. Fluorescence resonance energy transfer (FRET)-based target engagement
experiments proved the binding of LR to TS in cells with good target specificity. In lysates of
HEK293T cells, 2.5 micromoles/L of LR bound hTS, whereas only 30 nanomoles/L of the inhibitor
interacted with other targets [19]. Proteomic experiments allowed the characterization of some proteins
that are modulated by the peptides and that characterize the mechanism of action. We observed that
the difference in binding sites between these peptides (allosteric) and such classical TS-active-site
inhibitors as PMX and RTX goes together with a different protein set modulation by the drugs [22].
This also held true for the proline derivatives that we designed after the LR peptide (see below),
a finding that points to a conserved mechanism of action in cells of LR and its proline mutants [20].
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This protein set modulation was observed in different types of ovarian cancer cell models such as
A2780, A2780/CP, IGROV-1, 2008, and C13* [17,20,21].
Closely connected with the intracellular activity is the low metabolic stability of the LR peptide [23].
Although a relatively fast proteolytic degradation did not prevent it from engaging the hTS target [19]
and exhibiting an effect on cancer cell growth, we still expect higher activity from an increase
in biostability.
An important drawback in the design of peptidic inhibitors of protein–protein interactions is
that peptides are often more conformationally disordered when excised from the stabilizing context
of their protein interface domain. The larger the disorder, the lower the affinity (i.e., the higher the
binding ∆G◦) for the targets [17]. Thus, identifying a bioactive conformation with a low conformational
disorder may be crucial to improving peptide activity.
The crystal structure of the hTS/LR complex showed that the peptide binding site has the shape
of an inverted cone (highlighted in green in Figure 1C,D), narrower at the top and broader at the
bottom, where the LR peptide arranges with a longer extended portion that involves residues from
Leu1 to Leu5 and a helical turn that involves the last three residues at the C-terminus. To improve
the activity of the LR and [d-Gln4]LR octapeptides, we sequentially mutated residues 1 to 7 to
proline, and examined the conformational and functional consequences of the introduction of this
rigidifying residue in three regions, namely, near the C- and the N-termini and in the central portion of
the peptides [20]. According to circular dichroism (CD) spectroscopic evidence, peptides [Pro1]LR,
[Pro2]LR, and [Pro3]LR shared with LR the long-extended geometry of residues from 1 to 5 and
similar tendencies to form compact helical turns that involve the residues near the C-terminus.
Molecular dynamics simulations on [Pro2]LR showed that such a conformational preference resulted
from intramolecular hydrogen bonds between CO(Gln4) and NH(Gln7) and between CO(Arg8) and,
as donors, NH(Cys3) and NH(Gln4). On the other hand, mutation to proline at positions 5 and especially
6 and 7 generated peptides with lower propensities for assuming ordered secondary structures, with a
distorted β-turn that included the Pro6 residue likely stabilized by a hydrogen bond between CO(Gln4)
and NH(Gln7). Finally, consistently with the presence of such a rigidifying residue as proline at central
positions, for [Pro4]LR and [Pro5]LR CD suggested a β-turn-like structure. Overall, the seven tested
proline-mutated octapeptides showed conformational propensities similar to those of the starting
peptide, LR, but more compact and ordered shapes. This structural feature, possibly combined with a
stabilization versus peptidase degradation, may explain the stronger inhibition of ovarian cancer cell
growth shown by [Pro3]LR and [Pro4]LR relative to the lead peptide, LR [20].
Altogether, these observations on proline mutants confirm the value of these peptides as potential
anticancer compounds. They also represent a starting point to develop new peptides that could enhance
the positive features observed, in particular the lower structural flexibility and higher metabolic stability
while maintaining the allosteric mechanism of hTS inhibition of the linear peptides, by binding at the
protein interface. These features are expected to ensure a reduced hTS activity and also a reduced
protein level even in platinum drug-resistant ovarian cancer cells. With this aim, we decided to
move from linear peptides to cyclic peptides (cPs) that are known to show lower flexibility than the
corresponding linear peptides and higher stability towards peptidase attack than the corresponding
linear peptides [24,25]. In addition, peptide cyclization is known to improve such pharmacokinetic
properties as membrane permeability and bioavailability [26] that are important general features for
drug-like compounds. In the present work, we designed cPs involving 5–8 amino acid (AA) closures
corresponding to the turn at the C-terminus of the LR peptide and an extended 0–2 AA chain at the
N-terminus (see Figure 2). These cPs were synthesized, and their enzyme and cancer cell growth
inhibition properties detected. Our work successfully allowed the identification of one important hit
compound showing both hTS allosteric inhibition and cancer cell growth inhibition and other peptides
with IC50 below 10 µM towards all ovarian cancer cells tested.
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2. Results and Discussion
2.1. Design of Cyclic Peptides
The design of 10 new cyclic derivatives was performed according to the conformational studies on
LR (Leu1-Ser2-Cys3-Gln4-Leu5-Tyr6-Gln7-Arg8) and its more rigid d-Gln4 diastereomer, [d-Gln4]LR,
and Pro3 derivative, [Pro3]LR. Since the C-terminus of these three peptides folds in a helical-type
conformation occupying the basis of the conic binding cavity (Figure 1C,D), and in order to maintain
the inhibition mechanism, we wanted to preserve this peculiar binding cavity for the new cyclic
peptides giving them a noose-knot shape (Figure 2). Disulfide bonds are largely adopted for initial
attempts to explore the efficacy of newly designed cPs [27]. The cPs’ delivery to the cancer cells is
expected to happen using the peptides as such or by delivery through the SAINT-PhD system that we
successfully adopted in our previous work with the linear peptides [17–20]. In this latest case, the cPs
were complexed with the polymeric molecules of the delivery system, protected by protease attack
and other chemical modifications up to when they were released intracellularly [17,21,23,28].
The cPs’ design aimed at exploring the functional consequences, in terms of both hTS
inhibition and cytotoxicity, of such structural determinants as the relative sizes of the “linear”
N-terminus-containing portion and of the C-terminus-containing cycle as well as the conformational
rigidity of the latter. Peptides 1 and 2 (Figure 3) are the direct cyclic derivatives of the
open-chain peptide LR with, respectively, six-amino-acid and seven-amino-acid cycles. In peptide 1
(Leu-Ser-c[Cys-Gln-Leu-Tyr-Gln-Arg-CAM]), the aminoacidic sequence of LR was left unaltered and
the Cys3 was bound in a 6-term cycle with the Arg8 derivatized for this purpose at the C-terminus
with a subunit of cysteamine (CAM). In contrast, in peptide 2 (Leu-c[Cys-Ala-Gln-Leu-Tyr-Gln-Cys]),
in order to expand the cyclic peptide in a 7-term ring, an alanine was introduced in position
3 and the cycle was generated by connecting Cys2 with Cys8, which replaced the original Ser2
and Arg8, respectively (Figure 3). Peptides 3–5 derived from the cyclization of [d-Gln4]LR
(Leu-Ser-Cys-d-Gln-Leu-Tyr-Gln-Arg). Peptide 3 (Leu-Ser-c[Cys-d-Gln-Leu-Tyr-Gln-Arg-CAM])
is the direct diastereomer of peptide 1 at Gln4. To evaluate the importance of the cycle
dimension, in peptide 4 (Leu-Ser-c[Cys-d-Gln-Leu-Tyr-Gln-Cys]) a 6-term ring was obtained by
replacing Arg8 of the linear peptide with Cys, leaving unaltered Cys3. In contrast, in peptide 5
(Leu-Ser-c[Cys-d-Gln-Leu-Tyr-Cys]-Arg), a constrained 5-term ring was generated by introducing
a cysteine in position 7 and leaving unaltered the original terminal arginine residue (Figure 3).
Starting from the partially constrained [Pro3]LR (Leu-Ser-Pro-Gln-Leu-Tyr-Gln-Arg), peptides 6–10
were designed and synthesized preserving Pro3. In peptide 6 (Leu-c[Cys-Pro-Gln-Leu-Cys]-Gln-Arg),
the Ser2 was replaced with a cysteine and a 5-term cycle was generated with a residue of
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cysteine introduced at position 6 in the place of the original tyrosine. Moreover, in order to
evaluate the influence of the ring size in these Pro3 derivatives, we explored the expansion of
the ring into 6-term, 7-term, and 8-term cycles (peptides 7, Leu-c[Cys-Pro-Gln-Leu-Tyr-Cys]-Arg, 8,
Leu-c[Cys-Pro-Gln-Leu-Tyr-Gln-Cys], and 9, Leu-c[Cys-Pro-Gln-Leu-Tyr-Gln-Arg-CAM], respectively).
To this end, the second residue of cysteine necessary to generate the disulfide bond with Cys2 was
introduced to replace Gln7 of the peptide [Pro3]LR (peptide 7) or the terminal Arg8 (peptide 8).
In peptide 9, the Arg8 was derivatized for this purpose at the C-terminus with a subunit of CAM.
Finally, in order to evaluate the importance in these cPs of the involvement of the N-terminus portion in
the cycle, we generated the fully annular peptide 10 (c[Cys-Ser-Pro-Gln-Leu-Tyr-Gln-Cys]) by replacing
both Leu1 and Arg8 with Cys (Figure 3).
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2.2. Chemistry
The linear peptides were synthesized according to published methods [29] using Fmoc chemistry
with a Syro XP multiple peptide synthesizer (MultiSynTech GmbH, Witten, Germany). Wang’s resin
(for the synthesis of peptides 2, 4–8, and 10) or (CAM)-2-chlorotrityl resin (for the synthesis of peptides 1,
3, and 9) were used as the solid support [30]. The linear peptides were grown with deprotection/coupling
cycles until the desired resin-bound peptide was completed. Coupling was performed using
Fmoc-protected amino acids and diisopropylcarbodiimide (DIPCDI) and hydroxybenzotriazole (HOBt)
as coupling reagents in dimethylformamide (DMF) at room temperature for 1.5 h. Deprotection was
achieved with 40% of piperidine in DMF. The linear peptides were unbounded from the resin using a
mixture of trifluoroacetic acid (TFA), water, phenol, and triisopropylsilane (TIPS) at room temperature
for 1 h. Finally, the cyclization was performed solubilizing the linear purified analog in a mixture
of H2O, DMSO, and TFA and reacted at room temperature for one day [31]. Both linear and cyclic
peptides were purified by preparative HPLC (Scheme 1).
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2.3. Human Thymidylate Synthase Inhibitory Activity
All synt esized cPs were screened for the ability to inhibit hTS and the results are reported in
Table 1, where they are compared with the parent peptides, LR, [d-Gln4]LR, and [Pro3]LR [18,20].
All cPs showed higher water solubility than the parent linear peptides, and were first screened at
500 µM. Then, for the active ones, IC50 was measured reaching concentrations up to 3 mM. In the case
of the linear peptides, we could only test the compounds up to 100 µM.
To track structure–activity relationships (SARs) and gain information about the relevant structural
features that influence the inhibition potency, we analyzed the biological data as reported below.
The derivatives of LR with a 6-AA cycle, cP 1 (Leu-Ser-c[Cys-Gln-Leu-Tyr-Gln-Arg-CAM]), and a 7-AA
cycle, cP 2 (Leu-c[Cys-Ala-Gln-Leu-Tyr-Gln-Cys]), were 30- and 12-fold less active than LR, respectively,
with IC50s versus hTS of 2125 and 900 µM. cPs 3 (Leu-Ser-c[Cys-d-Gln-Leu-Tyr-Gln-Arg-CAM]),
4 (Leu-Ser-c[Cys-d-Gln-Leu-Tyr-Gln-Cys]), and 5 (Leu-Ser-c[Cys-d-Gln-Leu-Tyr-Cys]-Arg), derived
from the diastereomer [d-Gln4]LR with 6-, 6- and 5-AA ring closures were inactive at 500 µM. Because
cP 3 is the analog of cP 1 with D-Gln4, contrary to what was found with the corresponding open-chain
octapeptides, the D-chirality of Gln4, with the associated slightly larger rigidity, did not favor the
anti-hTS activity of these 6-AA-ring cyclic peptides. Low, if any, inhibitory activities were also found
with three out of the four cyclic analogs of [Pro3]LR, that is, with cPs expectedly featuring a narrower
conformational freedom at Pro3, near the “knot”, relative to the corresponding Gln cyclic peptides.
Peptides 6 (Leu-c[Cys-Pro-Gln-Leu-Cys]-Gln-Arg) and 9 (Leu-c[Cys-Pro-Gln-Leu-Tyr-Gln-Arg-CAM]),
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with 5- and 7-AA rings, respectively, were inactive at 500 µM both at room temperature and at 37 ◦C.
On the other hand, a modest inhibitory activity (hTS IC50 of 856 µM) was detected for peptide 8
(Leu-c[Cys-Pro-Gln-Leu-Tyr-Gln-Cys]), the 7-AA-ring cP that differed from cP 2 for the Ala-to-Pro
replacement at position 3. Given the similar activity between cP 2 and 8, we must conclude that the
Pro3 near the “knot” does not contribute to improving hTS inhibition of these 7-AA-ring cPs. Among
the cPs derived from [Pro3]LR, peptide 7 (Leu-c[Cys-Pro-Gln-Leu-Tyr-Cys]-Arg), featuring a 6-AA
ring, shows an inhibitory potency (hTS IC50 of 148 ± 40 µM) quite comparable with those of the
lead peptides, LR and [d-Gln4]LR (Table 1). The kinetic inhibition pattern of cP 7 was thus further
investigated and, in keeping with the inhibition behavior of the parent lead peptides [17,21], found to
suggest an allosteric mechanism, with apparent values of KI and KI′ similar to the IC50 value, namely,
120–150 µM (Figure S1, Supplementary Materials).
Table 1. hTS inhibitory activity of the previously assessed peptides LR, [d-Gln4]LR, and [Pro3]LR
and the new cyclic peptides 1–10. The assay was performed under stirring to prevent precipitation
of the peptides and at room temperature (20–22 ◦C). To improve solubility, peptides inactive at room
temperature were also tested at 37 ◦C.
Compound Primary Sequence % in hTS
a
(IC50 in µM) a
LR Leu-Ser-Cys-Gln-Leu-Tyr-Gln-Arg (75) b
[d-Gln4]LR Leu-Ser-Cys-d-Gln-Leu-Tyr-Gln-Arg (68) b
[Pro3]LR Leu-Ser-Pro-Gln-Leu-Tyr-Gln-Arg 25% at 100 µM c
1 Leu-Ser-c[Cys-Gln-Leu-Tyr-Gln-Arg-CAM] 25% at 400 µM and r.t. under stirring(2125)
2 Leu-c[Cys-Ala-Gln-Leu-Tyr-Gln-Cys] 36% at 400 µM and r.t. under stirring(900)
3 Leu-Ser-c[Cys-d-Gln-Leu-Tyr-Gln-Arg-CAM] N.I. at 500 µM and r.t.N.I. at 500 µM and 37 ◦C under stirring
4 Leu-Ser-c[Cys-d-Gln-Leu-Tyr-Gln-Cys] N.I. at 500 µM and r.t.N.I. at 500 µM and 37 ◦C under stirring
5 Leu-Ser-c[Cys-d-Gln-Leu-Tyr-Cys]-Arg N.I. at 500 µM and r.t.N.I. at 500 µM and 37 ◦C under stirring
6 Leu-c[Cys-Pro-Gln-Leu-Cys]-Gln-Arg N.I. at 500 µM and r.t.N.I. at 500 µM and 37 ◦C under stirring
7 Leu-c[Cys-Pro-Gln-Leu-Tyr-Cys]-Arg
76% at 500 µM, 59% at 100 µM and r.t. under stirring
(148)
Allosteric inhibition profile (see Figure S1)
8 Leu-c[Cys-Pro-Gln-Leu-Tyr-Gln-Cys] 38% at 500 µM and r.t. under stirring(856)
9 Leu-c[Cys-Pro-Gln-Leu-Tyr-Gln-Arg-CAM] N.I. at 500 µM and r.t.N.I. at 500 µM and 37 ◦C under stirring
10 c[Cys-Ser-Pro-Gln-Leu-Tyr-Gln-Cys] 50% at 500 µM and r.t. under stirring(474)
N.I., No inhibition; r.t., room temperature. a standard error is ±20% of the value; b Ref. [18]; c Ref. [20].
Finally, the fully cyclic peptide 10 (c[Cys-Ser-Pro-Gln-Leu-Tyr-Gln-Cys]) showed an hTS IC50 of
484 µM, and was thus a slightly better inhibitor than the similar (except for the first two residues)
7-AA-ring cP 8 (Leu-c[Cys-Pro-Gln-Leu-Tyr-Gln-Cys]), and a slightly worse inhibitor than cP 7
(Leu-c[Cys-Pro-Gln-Leu-Tyr-Cys]-Arg) that differs from cP 10 in the size of the cycle and in the N- and
C-terminus residues.
In general, moving from the linear peptides to their cyclic analogs, the structural change is relevant.
Indeed, as the data reported in Table 1 show, the types of cyclization we performed turned out to be
rather detrimental for the inhibitory activity towards the hTS target. This suggests that the ring closure,
even with the different features considered in the design, was complex and that the cPs could not fit
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properly into the cone-shaped interface binding site. Importantly, compound 7 shows an interesting
allosteric inhibition of hTS.
cP 7 represents the most active compound stemming from the SAR analysis, and its inhibition is
specific as demonstrated by the allosteric inhibition. On the other hand, it is clear that small changes in the
structures reflect large changes in the overall structural profile and this causes a significant activity decrease.
2.4. Cytotoxicity
To evaluate the inhibition of cancer cell growth by the 10 cPs, we transfected them up to 50 µM into
three ovarian cancer (OC) cell lines, namely, IGROV-1, A2780, and their cisplatin-resistant counterparts
A2780/CP. These cell lines were chosen to compare the cytotoxicities of the cPs with those of the
open-chain peptides LR, [d-Gln4]LR, and [Pron]LR [17,20,21]. We selected A2780 and its platinum
drug-resistant cell counterpart A2780/CP to observe if the new anti-hTS inhibitors could overcome
platinum drug resistance. IGROV-1 is typically expressing higher than normal hTS levels, showing a
lower sensitivity to 5-FU, a prodrug inhibitor with a different biological mechanism compared to the
peptides [20,22]. The three cell lines were considered a sufficient representative number of cancer cell
models for our screening purposes. We first attempted to deliver the cPs directly to the cancer cells,
but we could not observe any inhibitory effect (data not shown). For the transfection experiments,
we employed the same peptide delivery system, SAINT-PhD, previously used in the cellular assays of
the open-chain peptides [17,20,21]. Dose–response curves for all compounds are shown in Figures 4





Figure 4. Dose–response curves of the effect of the cyclic peptides on cell growth of IGROV-1 cells. 
Panel A: 5 (blue triangles up), 3 (red triangles down), 9 (red triangles up), 7 (blue squares), 2 (red 
diamonds), 6 (red squares), 1 (blue triangles down). Panel B: [D-Gln4]LR (red hexagons), 10 (blue 
diamonds), 4 (blue circles), 8 (red circles). Data are mean values with standard deviation. Statistical 
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Figure 4. Dose–response curves of the effect of the cyclic peptides on cell growth of IGROV-1 cells. Panel
A: 5 (blue triangles up), 3 (red triangles down), 9 (red triangles up), 7 (blue squares), 2 (red diamonds),
6 (red squares), 1 (blue triangles down). Panel B: [d-Gln4]LR (red hexagons), 10 (blue diamonds),
4 (blue circles), 8 (red circles). Data are mean values with standard deviation. Statistical significance
by two-sided Student’s t-test and ANOVA followed by Tukey’s multiple comparison test, * p < 0.05;
** p < 0.01; *** p < 0.001.
Quite at variance with the TS-inhibitory activities, peptide 5 (Leu-Ser-c[Cys-D-Gln-Leu-Tyr-Cys]
-Arg) was the most effective among the 10 tested cPs against all three cell lines, with IC50 values
lower than 10 µM, comparable with those of its open-chain parent, [d-Gln4]LR, and lower than 5-FU
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(Figures 6A and 7). cPs 3, derived from [d-Gln4]LR, and 9, 7, and 10, all derived from [Pro3]LR,
showed intermediate cytotoxicities versus IGROV-1 cells at 10 and 25 µ M; cPs 2, 6, 1, 4, and 8
were the least active versus these cells. However, the A2780 and A2780/CP cell lines were much
more sensitive to all of the 10 cPs except 6, the peptide derived from [Pro3]LR with a 5-AA cycle
(Figure 5B). As with the IGROV-1 cells, peptide 5 was the most potent one, together with peptide 9
(Leu-c[Cys-Pro-Gln-Leu-Tyr-Gln-Arg-CAM]) in the case of the cisplatin-resistant line. Compounds 4, 5,
8, and 9 showed IC50 values lower than 10 µM and comparable with those of the reference drugs 5-FU,
LR, and [d-Gln4]LR for at least one of the cell lines. The other four peptides, 2, 3, 7, and 10, showed
IC50 values below 25 µM versus at least one of the cell lines (Figure 7A,B).
All tested compounds show a higher cytotoxic activity towards one or more cancer cell lines than
hTS inhibition potency, thus supporting the idea that more targets and off-targets may be involved in
the complex cellular environment. A role in increasing the cellular growth inhibition activity is quite
certainly played by the increase in intracellular concentration of peptides relative to the extracellular
concentration—for peptide LR with C13 cells, we found the intracellular concentration to be 15 times
larger than the extracellular one when delivered through the SAINT-PhD system [23]. This ratio
depends on both the thermodynamics of cellular internalization (i.e., the factors that affect the chemical
potential of the peptide in the different compartments inside and outside cells) and the kinetics of
peptide degradation, the latter being more relevant within cells than in the extracellular medium where
they are protected from degradation by inclusion into the SAINT-PhD delivery system [23].
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Figure 5. Dose–response curve of the effect of the cyclic peptides on the cell growth of A2780 (panel A)
and A2780/CP (panel B) cell lines: 5 (blue triangles up), 9 (red triangles up), 4 (blue circles), 8 (red
circles), 10 (blue diamonds), 7 (blue squares), 2 (red diamonds), 3 (red triangles down), 1 (blue triangles
down), 6 (red squares). Data are mean values with standard deviation. Statistical significance by
two-sided Student’s t-test and ANOVA followed by Tukey’s multiple comparison test, * p < 0.05;
**; p < 0.01; *** p < 0.001.




Figure 6. IC50 values for the inhibition of cell growth of IGROV-1 human ovarian cancer cells by the
tested peptides. IC50 values of the 10 cyclic peptides (panel A, green bars) and of the 7 prolyl peptides
(panel B, dark cyan bars) compared with 5-FU, LR, and [d-Gln4]LR. Values are means ± SD of three
separate experiments performed in duplicate.
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Figure 7. IC50 values of the cyclic peptides on cell growth of A2780 (A) and A2780/CP (B) human
ovarian cancer cell lines. Values are means ± SD of three separate experiments performed in duplicate.
3. Conclusions
TS is one of the best-known anticancer targets. Its classical inhibitors bind at the substrate
or cofactor binding pockets. However, upon prolonged treatment in the clinic, these inhibitors
induce drug resistance mechanisms also related to TS overexpression. Ovarian cancer resistant to
platinum drugs shows cross-resistance with classical hTS inhibitors; therefore, treatments with these
drugs cannot circumvent the resistance problem. We previously identified some octapeptides that
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allosterically inhibited hTS without causing its cellular overexpression. Among them, peptide LR and
its diastereomer [d-Gln4]LR were the most interesting ones. The X-ray crystallographic structure of the
hTS/LR complex provides conformational details on the binding mode of LR at the protein interface,
showing that it occupies a conic space region. The occurrence of an allosteric inhibition was confirmed
by the inhibition pattern. To produce more potent inhibitors by decreasing the conformational disorder
of these peptides, we first mildly rigidified the open-chain LR peptide by introducing a proline residue
along its sequence and then designed 10 cyclic peptides from either LR, [d-Gln4]LR, or [Pro3]LR. Most
of the synthesized peptides preserved one or the other of the residues that contributed to increase the
TS inhibitory activity and cancer cell growth inhibition, namely, D-Gln4 and Pro3.
Peptides 7 (Leu-c[Cys-Pro-Gln-Leu-Tyr-Cys]-Arg), 8 (Leu-c[Cys-Pro-Gln-Leu-Tyr-Gln-Cys]),
and 10 (c[Cys-Ser-Pro-Gln-Leu-Tyr-Gln-Cys]) are the three best hTS inhibitors among the 10 tested cPs.
All of them feature, at position 3, a proline residue, which, in contrast with the D-Gln4 residue, can
rigidify the conformations of the three cyclic peptides in a way that is useful for inhibiting hTS. Their
cycles include, in order of increasing anti-hTS activity, 6 (cP 7), 8 (cP 10), and 7 AA (cP 8). The cycle size,
therefore, is not a strong structural predictor of the inhibitory activity, provided it is larger than 5 AA
(non-inhibiting cPs 5 and 6). Complementarily, an extended N-terminus portion in these noose-knot
peptides, here either absent (cP 10) or consisting in only one residue (cPs 7 and 8), does not seem to be
relevant for their abilities to inhibit hTS.
Of the two cPs with a 5-AA ring, peptide 6, inactive versus hTS, was also almost non-cytotoxic
towards the three cell lines employed. On the other hand, peptide 5, also inactive as an hTS inhibitor at
the tested concentrations, was the most cytotoxic among the 10 cPs.
The differences between the hTS inhibitory activities and the cytotoxicities are due to many factors
that may influence the activity of a drug during the different steps of the membrane penetration
process and target engagement. The IC50s determined from cell growth inhibition were systematically
lower, or much lower, than those associated with hTS inhibition. The characterization of the cellular
mechanism of action is however beyond the scope of this preliminary note. The efficiencies of all
mentioned factors that may influence the cPs’ intracellular activity are likely determined by structural
descriptors of the cyclic peptides that are different from those that control their affinities towards
recombinant hTS. For example, different cyclic peptides may accommodate differently into the delivery
system vesicles, thus yielding SAINT-PhD/cPs complexes with different chemical potentials that are
completely unrelated to the affinities of the cPs for hTS. Or, again, as is the case with the [Pron]LR
relative to the LR peptides [20–22], different cyclic peptides may be differently prone to intracellular
degradation by peptidases and, hence, the observed lack of quantitative correlation between the hTS
inhibitory activities and the cytotoxicities.
While these results stimulate many questions concerning the efficiency of cellular internalization
and intracellular stability and the intracellular mechanism of action of the cPs, questions that are
being addressed in scheduled experiments, our first screening of these 10 cPs leaves us with a cP,
compound 5, that was active against all cancer cells with IC50s lower than 10 µM, and a cP, compound
7, that inhibited cancer cell growth and was by far the best hTS inhibitor. Thus, while compound 5
may give us hints about the structural requirements necessary to achieve good activity towards cancer
cells, compound 7 can be considered a starting lead useful for the further chemical optimization of
hTS-inhibiting cyclic peptides.
4. Materials and Methods
4.1. Synthesis and Purification
4.1.1. Linear Peptides
Linear LR analogs were synthesized using a Syro XP multiple peptide synthesizer (MultiSynTech
GmbH, Witten, Germany). Chemicals and solvents were purchased from Sigma Aldrich (St. Luis, MO,
United States). Wang resin preloaded with the C-terminal amino acid or (CAM)-2-chlorotrityl
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resin were used as a solid support for the synthesis of the derivatives. Fmoc-amino acids
(4 equivalents) were sequentially coupled to the growing peptide chain using DIPCDI and HOBt
(N,N’-diisopropylcarbodiimide/1-hydroxybenzotriazole) (4 equivalents) as activating agents at room
temperature for 1 h. Deprotection of the Fmoc-growing peptide was performed with 40% piperidine in
DMF followed by the coupling with the subsequent amino acids. Deprotection and coupling cycles
were repeated until the desired peptide-bound resin was completed. The protected peptide-resin was
treated with reagent B (trifluoroacetic acid (TFA), H2O, phenol, and TIPS 88:5:5:2 v/v; 10 mL per 0.2 g
of resin) [30] at room temperature for 1.5 h. After filtration of the resin, the solvent was concentrated
in vacuo and the residue triturated with ethyl ether. Crude peptides were purified by preparative
reversed-phase HPLC using a Water Delta Prep 3000 system with a Jupiter column C18 (250 × 30 mm,
300 A, 15 µm spherical particle size, Waters Corporation, Milford, MA, United States). The column was
perfused at a flow rate of 20 mL/min with a mobile phase containing solvent A (5%, v/v, acetonitrile in
0.1% TFA) and a linear gradient from 0 to 50% of solvent B (60%, v/v, acetonitrile in 0.1% TFA) over
25 min for the elution of peptides. Analytical HPLC analyses were performed on a Beckman 116 liquid
chromatograph equipped with a Beckman 166 diode array detector (Beckman Coulter, Brea, CA, United
States). Analytical purity of the peptides was assessed using a Zorbax C18 column (4.6 × 150 mm,
3 µm particle size, Agilent, Santa Clara, CA, United States) with the above solvent system (solvents A
and B) programmed at a flow rate of 0.7 mL/min using a linear gradient from 0% to 100% B over 25 min.
All analogs showed ≥95% purity when monitored at 220 nm. Molecular weight of final compounds
was determined by a mass spectrometer ESI Micromass ZMD-2000 (Waters Corporation, Milford, MA,
United States) and similar to the MS spectra already reported [21].
4.1.2. Cyclic Peptides (1–10)
To carry out and assess peptide cyclization, we followed a chemical procedure previously adopted
by some of us for the synthesis of cyclic urotensin II analogs [31]. In short, the respective linear purified
peptides were dissolved in a mixture of H2O, DMSO, and TFA (75:25:0.1 v/v) at the concentration of
1mg/mL and stirred at room temperature for 24 h. We monitored the reaction by analytical HPLC,
mass spectrometry, and the Ellman test, being careful to prevent the final Ellman’s test solution to
become acidic [32]. After partial evaporation of the solvent, the product was purified by preparative
HPLC as mentioned above to yield the desired cyclic compound (Supplementary Materials).
Leu-Ser-c[Cys-Gln-Leu-Tyr-Gln-Arg-CAM-] (1)
15% yield. Retention time (Rt): 8.63 min. ESI-MS [M + H]+ calcd: 1067.513; found: 1068.006.
Leu-c[Cys-Ala-Gln-Leu-Tyr-Gln-Cys] (2)
30% yield. Rt: 11.08 min. ESI-MS [M + H]+ calcd: 939.407; found: 939.852.
Leu-Ser-c[Cys-D-Gln-Leu-Tyr-Gln-Arg-CAM-] (3)
13% yield. Rt: 8.66 min. ESI-MS [M + H]+ calcd: 1067.513; found: 1067.974.
Leu-Ser-c[Cys-D-Gln-Leu-Tyr-Gln-Cys-] (4)
18% yield. Rt: 12.47 min. ESI-MS [M + H]+ calcd: 955.402; found: 955.402.
Leu-Ser-c[Cys-D-Gln-Leu-Tyr-Cys-]Arg (5)
29% yield. Rt: 10.74 min. ESI-MS [M + H]+ calcd: 983.444; found: 983.904.
Leu-c[Cys-Pro-Gln-Leu-Cys-]Gln-Arg (6)
25% yield. Rt: 8.42 min. ESI-MS [M + H]+ calcd: 958.460; found: 958.756.
Leu-c[Cys-Pro-Gln-Leu-Tyr-Cys-]Arg (7)
18% yield. Rt: 9.33 min. ESI-MS [M + H]+ calcd: 993.465; found: 993.561.
Leu-c[Cys-Pro-Gln-Leu-Tyr-Gln-Cys-] (8)
22% yield. Rt: 12.47 min. ESI-MS [M + H]+ calcd: 965.422; found: 966.074.
Leu-c[Cys-Pro-Gln-Leu-Tyr-Gln-Arg-CAM] (9)
10% yield. Rt: 9.11 min. ESI-MS [M + H]+ calcd: 1078.331; found: 1078.251.
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c[Cys-Ser-Pro-Gln-Leu-Tyr-Gln-Cys] (10)
25% yield. Rt: 9.23 min. ESI-MS [M + H]+ calcd: 939.370; found: 939.730.
4.2. Thymidylate Synthase Purification, Characterization, and Inhibition
hTS was purified as previously reported [21]. The enzyme solution was thawed the day of the
experiment and the enzyme concentration was determined by UV−Vis spectroscopy (Varian Cary
100, Agilent, Santa Clara, CA, USA) using ε280 = 89000 M−1 cm−1 and Mr = 74 229. The thawed
protein solution was kept constantly at 4 ◦C. In this condition, the enzyme was able to reproduce
normal kinetic activity values (KM dUMP = 10−12 µM, KM mTHF = 4−6 µM, kcat = 0.8−0.9 s−1).
The peptide solution was mixed or vortexed in order to help solubilization; the precise concentration
was determined through UV−Vis spectroscopy. A stock solution of mTHF was prepared in carbonate
buffer. The stock was prepared in the range of 5 to 6 mM. A stock solution of dUMP was prepared in
bidistilled water in the range of 10−12 mM. Peptide inhibitors were tested without incubation with hTS
in phosphate buffer, pH 6.9, at 25 ◦C. A 1 mL amount of assay buffer consisted of 50 mM TES, pH 7.4,
containing 25 mM MgCl2, 6.5 mM HCHO, 1 mM EDTA, 75 mM β-mercaptoethanol (β-ME), 0.120 mM
dUMP, and 0.060 mM mTHF. Following the addition of the enzyme (300 nM) and inhibitor mixture,
the absorbance was monitored at 340 nm in a UV−Vis spectrophotometer for 3 min. In the control
sample, an equal aliquot of enzyme alone was added. hTS activity inhibition percentages (I%) values
were measured at 0.100−3000 µM concentration of inhibitor. The concentration of the peptide that
showed the 50% activity inhibition was measured for the most active peptides. The kinetic inhibition
pattern was studied for compound 7 [12]. The inhibition values are expressed as mean ± SEM; n = 3.
4.3. Cell Lines
The IGROV-1, A2780, and A2780/CP human ovarian cancer cell lines [33] were grown as monolayer
in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum and 50 µg/mL gentamycin
sulfate (Euroclone, Devon, UK). Cultures were equilibrated with humidified 5% CO2 in air at 37 ◦C.
The cDDP-resistant variant A2780/CP cell line, derived from the parent A2780 cell line, is about 10-fold
resistant to cDDP and was developed by monthly exposure to cDDP, followed by chronic exposure to
stepwise increases in cDDP concentration. All studies were performed in Mycoplasma negative cells, as
routinely determined with the MycoAlert Mycoplasma detection kit (Lonza, Walkersville, MD, USA).
4.4. Treatment with Peptides in Presence of SAINT-PhD Delivery System
Treatment with each peptide was performed according to the standard transfection protocol
of the SAINT-PhD delivery system (Synvolux Therapeutics, Leiden, Netherlands) [17,21,23,28,34].
Complexes of peptide (µg) with SAINT-PhD (µL) were prepared at appropriate ratios corresponding
to the approximate µM concentrations indicated. For each protein sample, complexes were prepared
as follows: for the treatment of a 24-well plate, the appropriate amount of each peptide was diluted
in HBS, then SAINT-PhD was pipetted into the solution without vortexing; then, the mixture was
incubated for 5 min at room temperature, and filled up to 500 µL with serum-free medium. The culture
medium was aspirated from the cells, the SAINT-PhD/peptide complex was added to the wells and
incubated 4 h (37 ◦C, 5% CO2). Afterward, complete RPMI was added to reach the appropriate volume
for maintaining the cell culture for the duration of the experiments.
4.5. Cytotoxicity Assay of Peptides
Cell growth was determined using a modified crystal violet assay [35]. On selected days, the tissue
culture medium was removed, and the cell monolayer fixed with methanol and stained with 0.2%
crystal violet solution in 20% methanol for at least 30 min. After being washed several times with
distilled water to remove excess dye, the cells were left to dry. The incorporated dye was solubilized
in acidified isopropanol (1N HCl: 2-propanol, 1:10). After appropriate dilution, absorbance was
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determined spectrophotometrically at 540 nm. The extracted dye was proportional to cell biomass.
The percentage of cytotoxicity was calculated by comparing the absorbance of cultures exposed to the
drug to unexposed (control) cultures.
4.6. Statistical Analysis
Data indicate mean values and standard deviation. In addition, p-values were calculated with
the two-sided Student’s t-test and ANOVA followed by Tukey’s multiple comparison test. * p < 0.05,
** p < 0.01; *** p < 0.001.
Supplementary Materials: The following supplementary material are available online. Figure S1: Allosteric
inhibition profile for peptide 7; Mass spectra and analytical HPLC chromatograms of the final cyclic peptides.
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